Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Change in Accured Expenses (2018 - 2025)

Historic Change in Accured Expenses for Abvc Biopharma (ABVC) over the last 11 years, with Q3 2025 value amounting to -$33632.0.

  • Abvc Biopharma's Change in Accured Expenses rose 1581.27% to -$33632.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $100486.0, marking a year-over-year increase of 21318.68%. This contributed to the annual value of $152819.0 for FY2024, which is 7607.58% down from last year.
  • According to the latest figures from Q3 2025, Abvc Biopharma's Change in Accured Expenses is -$33632.0, which was up 1581.27% from -$16865.0 recorded in Q2 2025.
  • Abvc Biopharma's Change in Accured Expenses' 5-year high stood at $678094.0 during Q2 2023, with a 5-year trough of -$540519.0 in Q3 2021.
  • For the 5-year period, Abvc Biopharma's Change in Accured Expenses averaged around $44763.9, with its median value being $40113.0 (2025).
  • Per our database at Business Quant, Abvc Biopharma's Change in Accured Expenses crashed by 18298.63% in 2022 and then soared by 122398.62% in 2024.
  • Over the past 5 years, Abvc Biopharma's Change in Accured Expenses (Quarter) stood at $165777.0 in 2021, then soared by 106.17% to $341775.0 in 2022, then plummeted by 102.89% to -$9864.0 in 2023, then soared by 1223.99% to $110870.0 in 2024, then plummeted by 130.33% to -$33632.0 in 2025.
  • Its Change in Accured Expenses was -$33632.0 in Q3 2025, compared to -$16865.0 in Q2 2025 and $40113.0 in Q1 2025.